Effect of levofloxacin on the viability of intracellular Chlamydia pneumoniae and modulation of proinflammatory cytokine production by human monocytes

Diagn Microbiol Infect Dis. 2004 Nov;50(3):205-12. doi: 10.1016/j.diagmicrobio.2004.07.009.

Abstract

Although antibiotics are known to affect the intracellular growth of Chlamydia pneumoniae in acute infections, their efficacy in therapy for chronic infections, including atherosclerosis, remains debatable. Human monocyte-derived macrophages (MDM) obtained from monocytes of healthy donors were infected with C. pneumoniae AR-39 and treated with levofloxacin (8 microg/mL) immediately after infection (0 hours) or 24 hours after infection. Levofloxacin treatment at 24 hours, but not at 0 hours, resulted in a significant decrease in the number of C. pneumoniae inclusions within the MDM (p < 0.05). Also decreased were concentrations of proinflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, and IL-8 in the extracellular medium (p < 0.01). Viable counts in titrations remained similar to those in untreated controls. In summary, levofloxacin administered to MDM at serum-attainable levels 24 hours after C. pneumoniae infection significantly decreased inclusion counts and proinflammatory cytokine production, but did not eliminate the C. pneumoniae infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cell Line
  • Chlamydophila pneumoniae / drug effects*
  • Cytokines / biosynthesis*
  • Hepatocytes / microbiology
  • Humans
  • Levofloxacin*
  • Monocytes / drug effects*
  • Monocytes / immunology
  • Monocytes / microbiology
  • Ofloxacin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Cytokines
  • Levofloxacin
  • Ofloxacin